质子放疗用于复发性或转移性头颈部癌的姑息四联照射
Proton Radiotherapy for Recurrent or Metastatic Head and Neck Cancers with Palliative Quad Shot.
作者信息
Ma Jennifer, Lok Benjamin H, Zong Jingfeng, Gutiontov Stanley I, Cai Xin, Bell Andrew C, Shcherba Marina, Xiao Han, Sherman Eric J, Tsai Chiaojung Jillian, Riaz Nadeem, McBride Sean M, Cahlon Oren, Lee Nancy Y
机构信息
Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Albert Einstein College of Medicine, Bronx, NY, USA.
出版信息
Int J Part Ther. 2018 Spring;4(4):10-19. doi: 10.14338/IJPT-18-00003.1.
PURPOSE
Some patients with previously treated, unresectable, recurrent or metastatic head and neck malignancies are not amenable to curative-intent treatment. Here, we investigated the quad-shot (RTOG 8502) regimen of hypofractionated proton radiotherapy (RT) in that patient population.
MATERIALS AND METHODS
From 2013 to 2015, 26 patients with recurrent or metastatic cancers were treated with palliative proton RT to the head and neck with quad shot (3.7 Gy twice daily for 2 days). Patient characteristics and survival data were reviewed.
RESULTS
Seventeen (65%) patients received ≥ 3 quad-shot cycles and 23 (88%) had prior head and neck RT. Overall palliative response was 73% (n = 19). The most common presenting symptom was pain (50%; n = 13), which improved in 85% (n = 22) of all patients. The overall grade-1 acute-toxicity rate was 58% (n = 15), and no acute grade 3 to 5 toxicities were observed.
CONCLUSIONS
The proton quad-shot regimen demonstrates favorable palliative response and toxicity profile, even in patients that received prior RT.
目的
一些曾接受过治疗、无法切除、复发或转移性头颈部恶性肿瘤患者不适合进行根治性治疗。在此，我们研究了该患者群体中质子分割放疗（RT）的四程（RTOG 8502）方案。
材料与方法
2013年至2015年，26例复发或转移性癌症患者接受了姑息性质子头颈部放疗，采用四程方案（每日两次，每次3.7 Gy，共2天）。回顾了患者特征和生存数据。
结果
17例（65%）患者接受了≥3个四程周期治疗，23例（88%）患者曾接受过头颈部放疗。总体姑息反应率为73%（n = 19）。最常见的症状是疼痛（50%；n = 13），所有患者中有85%（n = 22）的疼痛症状得到改善。1级急性毒性总发生率为58%（n = 15），未观察到3至5级急性毒性反应。
结论
质子四程方案显示出良好的姑息反应和毒性特征，即使在曾接受过放疗的患者中也是如此。
Zotero 插件